Cytokinetics, Inc. Share Price Nasdaq
Stocks
US23282W1009
Biotechnology & Medical Research
|
End-of-day quote
Other stock markets
|
||
| - USD | - |
|
| 06-29 | Cytokinetics Insider Sold Shares Worth $266,390, According to a Recent SEC Filing | MT |
| 06-29 | Cytokinetics Seen Gaining From Myqorzo Momentum to Treat Heart Conditions, UBS Says | MT |
| Market Cap | 11.58B 10.16B 9.36B 8.72B 16.44B 1,101B 16.77B 113B 43.6B 540B 43.46B 42.52B 1,880B | P/E 2026 * |
-13.2x | P/E 2027 * | -18.3x |
|---|---|---|---|---|---|
| Enterprise Value | 10.99B 9.65B 8.88B 8.28B 15.61B 1,045B 15.93B 107B 41.4B 513B 41.27B 40.38B 1,785B | EV / Sales 2026 * |
101x | EV / Sales 2027 * | 27.9x |
| Free-Float |
98.23% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Cytokinetics, Inc.
| Manager | Title | Age | Since |
|---|---|---|---|
Robert Blum
CEO | Chief Executive Officer | 62 | 31/12/2006 |
Sung Lee
DFI | Director of Finance/CFO | 55 | 07/05/2024 |
| Chief Administrative Officer | 57 | 13/11/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Robert Blum
BRD | Director/Board Member | 62 | 31/12/2006 |
John Henderson
CHM | Chairman | 81 | 07/04/2022 |
Wendell Wierenga
BRD | Director/Board Member | 78 | 08/02/2011 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.94% | +3.48% | +72.94% | +131.54% | 56.21B | |
| +0.55% | +8.49% | +77.09% | +100.93% | 55.38B | |
| +0.93% | +4.11% | -12.64% | -12.98% | 23.75B | |
| +0.36% | +3.42% | +9.61% | +407.11% | 23.19B | |
| +3.64% | +8.34% | +39.81% | -5.88% | 18.14B | |
| +1.04% | +5.58% | +40.20% | -29.93% | 16.84B | |
| +1.49% | +17.24% | +174.91% | +344.55% | 15.86B | |
| -0.83% | +2.06% | +23.70% | +182.37% | 13.56B | |
| +7.20% | +13.33% | +42.13% | - | 12.97B | |
| Average | +1.91% | +6.94% | +51.97% | +139.71% | 26.21B | |
| Weighted average by Cap. | +1.61% | +6.60% | +56.51% | +132.07% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 109M 95.5M 87.9M 81.91M 154M 10.34B 158M 1.06B 410M 5.08B 408M 400M 17.67B | 393M 345M 318M 296M 558M 37.37B 570M 3.82B 1.48B 18.34B 1.48B 1.44B 63.84B |
| Net income | -805M -707M -650M -606M -1.14B -76.52B -1.17B -7.82B -3.03B -37.56B -3.02B -2.96B -131B | -653M -573M -528M -492M -928M -62.09B -946M -6.35B -2.46B -30.48B -2.45B -2.4B -106B |
| Net Debt | -583M -512M -472M -439M -829M -55.47B -845M -5.67B -2.2B -27.23B -2.19B -2.14B -94.76B | -601M -527M -485M -452M -853M -57.1B -870M -5.84B -2.26B -28.03B -2.25B -2.21B -97.54B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Select your edition
All financial news and data tailored to specific country editions
